drugset / Trial / NCT03538522

A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831

NCT03538522

Phase 2 Completed 126 enrolled Biomed Industries, Inc.
RandomizedParallel-groupQuadruple-blindOther

Summary

This study seeks to evaluate the efficacy and safety of NA-83 in subjects with mild cognitive impairment due to Alzheimer's Disease

Timeline

Start
2018-09-15
Primary completion
2019-09-30
Completion
2019-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CYCLO(PROLYLGLYCYL) Small molecule 10 mg Oral
Subject CYCLO(PROLYLGLYCYL) Small molecule 20 mg Oral
Subject CYCLO(PROLYLGLYCYL) Small molecule 40 mg Oral